Charles River Laboratories | CRL - Gewinn Vor Steuern

Aktienkurs
175.78
Täglich Wechseln
0.71 0.41%
Monatlich
5.02%
Jährlich
75.87%
Q2 Prognose
168.66




Gewinn Vor Steuern Veränderung Datum
Agilent USD 442M 1000K 2025-09
Align Technology USD 176.6M 81.86M 2025-12
Bio-Rad Laboratories USD 82.9M 331.1M 2025-09
Bruker USD -72.6M 73.1M 2025-09
Cardinal Health USD 598M 214M 2025-09
Charles River Laboratories USD 170.03M 98.62M 2025-09
Cigna USD 2.3B 274M 2025-09
CVS Health USD 1.35B 4.84B 2025-12
Danaher USD 1.08B 421M 2025-09
Dentsply International USD -230M 77M 2025-09
Elevance Health USD 215M 1.19B 2025-12
Galapagos EUR -221.49M 117.07M 2025-09
Hologic USD 229.7M 2.3M 2025-12
Humana USD 527M 214M 2025-09
Illumina USD 220M 86M 2025-09
Incyte USD 389.94M 92.37M 2025-12
Intrexon USD -60.48M 27.09M 2024-06
IQVIA Holdings USD 6.16B 5.84B 2025-09
Laboratory Of America USD 337M 32.3M 2025-09
Lonza CHF 624M 197M 2024-12
McKesson USD 1.4B 344M 2025-09
Merck EUR 1.29B 458.1M 2025-09
Mettler Toledo International USD 269.24M 20.58M 2025-09
Novartis USD 4.64B 445M 2025-12
Pfizer USD 3.33B 290M 2025-09
Quest Diagnostics USD 336M 57M 2025-09
Revvity USD 55.68M 115.97M 2025-09
Thermo Fisher Scientific USD 2.12B 295M 2025-12
United Therapeutics USD 444M 6M 2025-12
UnitedHealth USD 3.23B 1.16B 2025-09
Veradigm USD 35.3M 13.95M 2022-09
Waters USD 170.12M 7.57M 2025-09
West Pharmaceutical Services USD 170.1M 8.1M 2025-09